Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Axonal damage in acute multiple sclerosis lesions.
[Lyme disease in patients with multiple sclerosis: clinical, diagnostic and therapeutic features.]
Long-Term Results Underscore Value of Early MS Treatment
Inflammatory Response and Chemokine Expression in the White Matter Corpus Callosum and Gray Matter Cortex Region During Cuprizone-Induced Demyelination.
Functional assessment of magno, parvo and konio-cellular pathways; current state and future clinical applications.
Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.
Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions.
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection.
Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells.
Prevalence of human herpesvirus U94/REP antibodies and DNA in Tunisian multiple sclerosis patients.
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.
RORγt-specific transcriptional interactomic inhibition suppresses autoimmunity associated with TH17 cells.
CD44 is required for the migration of transplanted oligodendrocyte progenitor cells to focal inflammatory demyelinating lesions in the spinal cord.
Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.
Fingolimod for multiple sclerosis: a review for the specialist nurse.
T cell vaccination in multiple sclerosis: results of a preliminary study.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Yoga for multiple sclerosis: a systematic review and meta-analysis.
Modelling and Prediction of 25-Hydroxyvitamin D Levels in Norwegian Relapsing-Remitting Multiple Sclerosis Patients.
Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model.
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.
Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.

Pages